---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-24-000026"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-11-27T23:59:59+00:00"
generated_at: "2026-05-29T13:26:35.408380+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics sells Rare Pediatric Disease PRV for $150 million cash

## Summary
- Sale price of $150 million payable in cash upon closing to an affiliate of a large pharmaceutical company.
- PRV was awarded on November 13, 2024 with FDA approval of KEBILIDI (eladocagene exuparvovec-tneq) for AADC deficiency.
- Transaction subject to customary closing conditions including expiration of HSR Act waiting period.

## SEC filing metadata
- accession: 0001070081-24-000026
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-11-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000026/0001070081-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000026/tmb-20241126x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-24-000026
- JSON: https://secwatch.observer/filing/0001070081-24-000026.json
- Plain text: https://secwatch.observer/filing/0001070081-24-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.